Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.
about
On the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of Down syndromeConceptualizing neurodevelopmental disorders through a mechanistic understanding of fragile X syndrome and Williams syndromeFragile x syndromeTranscriptional Reactivation of the FMR1 Gene. A Possible Approach to the Treatment of the Fragile X SyndromeSynaptic Plasticity, a Prominent Contributor to the Anxiety in Fragile X SyndromeEmerging pharmacologic treatment options for fragile X syndromeNetworking in autism: leveraging genetic, biomarker and model system findings in the search for new treatmentsFragile X syndrome and targeted treatment trials.The role of glutamate and its receptors in autism and the use of glutamate receptor antagonists in treatment.Treatment of neurodevelopmental disorders in adulthoodTargeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromesDeveloping Medications Targeting Glutamatergic Dysfunction in Autism: Progress to DateThe unstable repeats--three evolving faces of neurological diseaseNegative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism.Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and BackAdvancing the understanding of autism disease mechanisms through geneticsReview of targeted treatments in fragile X syndromeHistopathologic characterization of the BTBR mouse model of autistic-like behavior reveals selective changes in neurodevelopmental proteins and adult hippocampal neurogenesisThe NIH Toolbox Cognitive Battery for intellectual disabilities: three preliminary studies and future directionsDe Novo Gene Disruptions in Children on the Autistic SpectrumEnhanced expression of ADCY1 underlies aberrant neuronal signalling and behaviour in a syndromic autism model.Electrocortical changes associated with minocycline treatment in fragile X syndrome.Progress toward therapeutic potential for AFQ056 in Fragile X syndrome.Psychophysiological responses to emotional stimuli in children and adolescents with autism and fragile X syndrome.From FMRP function to potential therapies for fragile X syndrome.Influence of stimulant-induced hyperactivity on social approach in the BTBR mouse model of autismAllosteric modulation of metabotropic glutamate receptors.mGluR5 ablation in cortical glutamatergic neurons increases novelty-induced locomotionCGG repeat in the FMR1 gene: size mattersDisrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome.Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome.Topological methods reveal high and low functioning neuro-phenotypes within fragile X syndrome.Partial mGlu₅ Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects.Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study.Psychiatric symptoms in boys with fragile X syndrome: a comparison with nonsyndromic autism spectrum disorder.Advanced pharmacotherapy evidenced by pathogenesis of autism spectrum disorder.Epilepsy drives autism in neurodevelopmental disorders.Fragile X Syndrome: Prevalence, Treatment, and Prevention in ChinaLithium: a promising treatment for fragile X syndrome.FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States
P2860
Q22241936-242D7558-92E1-4617-8718-4106F92C67E8Q24613296-086D2483-5813-4128-8948-CC9851FE94A5Q24633000-E17E2465-B4BA-45D9-ACE4-13C31E8AD29FQ26739927-E061FF5C-B318-426B-B193-2521479CA46EQ26745117-5D443DFC-DDCD-4F88-84F2-E0A1D5028106Q26829152-2491A770-3F9C-463F-857F-E035AC639024Q26850307-151E1170-17FC-4A56-8BD2-70AA528FC535Q26865162-685E0D49-B845-441D-A0E0-DE5E63992DA6Q26998975-7762A644-4142-4372-A7E1-F96AF906E466Q27000307-5A45C5F9-AF5E-44D6-BEDB-2B2DDAE819F5Q27023257-7AF75599-F662-434A-A107-4E93DB7A6463Q27025683-C77B2E42-D052-4D3F-A82F-44B5361288ECQ27025923-8BF6E6B6-6BCB-4D55-B669-F1193DB33CF6Q27329063-C0374047-C2A0-4A23-AA2C-C31E0D23B0C8Q27337360-2FA3D03F-8A1F-4305-9741-114DD5EC0AA0Q28069757-817F0552-5265-45D5-95A3-4EF22A323405Q28077180-A1F3E418-548A-4DC0-BB03-578F96A45244Q28390236-FEC24DF8-2603-4F95-8DB7-499362E13AA0Q29109561-3A1C5E34-1687-4A29-9A82-F9085D16A78EQ29394534-DDF91D0A-17CD-4C14-A9CB-93510ABF18B6Q30362378-234FDDA0-5DFE-41B7-B69B-998B42FF3001Q30378165-1ADD6EA7-B51E-4AA4-8DEE-98E4B430FF12Q30383696-B4B1A91B-6744-4E06-8C05-B5F54E9A2701Q30394865-4C73CC93-B6B4-450C-803E-1CC36A8E31F9Q30410502-C628877A-44FC-4083-AF64-C805D26451CEQ30439243-BCD23EB4-EC87-4FF5-8178-463BEDBB57DAQ30448534-6FC03E2C-6AB3-45E3-B602-263CC77FBA70Q30450936-7730BAFB-6A3A-474E-8BC8-8DB4686CE912Q30464036-65C5A962-7F82-48ED-914E-CCC884B5CC62Q30505749-7B7399C4-5B61-4B46-969C-8E1A82719CE4Q30574939-4BA3F019-3B86-4B61-9175-8B614616C33AQ30585077-B46C6DE6-69AB-421B-A4E0-8759E56D7731Q30709836-1E034310-2A31-492F-BA98-FFC6B4E9DD26Q31043571-72481053-8885-4F72-9EB8-A91FC28A7D54Q33565886-A8617386-D1BD-4A55-81B3-06A353C2A62CQ33618938-225C7036-8685-4232-87BF-6EBE03A85DFAQ33733577-510AD54F-B66F-49BE-93A0-0C46098714D6Q33766106-6C3AB5F6-F4EE-4760-AB5B-9D2ECAA9B63DQ33777951-FD20E2A9-7139-4293-ADE8-3DBE78559721Q33781086-80658B6D-6860-4FD7-98DF-2FDC272E75C3
P2860
Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Epigenetic modification of the ...... the mGluR5 antagonist AFQ056.
@ast
Epigenetic modification of the ...... the mGluR5 antagonist AFQ056.
@en
Epigenetic modification of the ...... the mGluR5 antagonist AFQ056.
@nl
type
label
Epigenetic modification of the ...... the mGluR5 antagonist AFQ056.
@ast
Epigenetic modification of the ...... the mGluR5 antagonist AFQ056.
@en
Epigenetic modification of the ...... the mGluR5 antagonist AFQ056.
@nl
prefLabel
Epigenetic modification of the ...... the mGluR5 antagonist AFQ056.
@ast
Epigenetic modification of the ...... the mGluR5 antagonist AFQ056.
@en
Epigenetic modification of the ...... the mGluR5 antagonist AFQ056.
@nl
P2093
P2860
P50
P1476
Epigenetic modification of the ...... the mGluR5 antagonist AFQ056.
@en
P2093
Amandine Brun
Annette Floesser
Aurore Curie
Baltazar Gomez-Mancilla
Charles Paulding
Danielle Martinet
Donald Johns
Elizabeth Berry-Kravis
Fabrizio Gasparini
Gerald Bussy
P2860
P356
10.1126/SCITRANSLMED.3001708
P407
P577
2011-01-01T00:00:00Z